Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005-2014)

Full text
Author(s):
Batschinski, Karen [1] ; Nobre, Alessandra [2] ; Vargas-Mendez, Ernesto [3] ; Tedardi, V, Marcello ; Cirillo, Juliana [2] ; Cestari, Greice [2] ; Ubukata, Rodrigo [2] ; Dagli, Maria Lucia Z. [4]
Total Authors: 8
Affiliation:
[1] Univ Sao Paulo, Sch Vet Med & Anim Sci, Lab Expt & Comparat Oncol, Dept Pathol, Av Prof Dr Orlando Marques 87, Sao Paulo - Brazil
[2] Univ Sao Paulo, Oncol Dept, Provet Vet Diagnost & Specialty Ctr, Av Divino Salvador 774, Sao Paulo - Brazil
[3] Univ Sao Paulo, Fac Pharmaceut Sci, Lab Diet Nutr & Canc, Av Prof Lineu Prestes 580, Sao Paulo - Brazil
[4] Tedardi, Marcello, V, Univ Sao Paulo, Sch Vet Med & Anim Sci, Lab Expt & Comparat Oncol, Dept Pathol, Av Prof Dr Orlando Marques 87, Sao Paulo - Brazil
Total Affiliations: 4
Document type: Journal article
Source: CANADIAN VETERINARY JOURNAL-REVUE VETERINAIRE CANADIENNE; v. 59, n. 9, p. 967-972, SEP 2018.
Web of Science Citations: 3
Abstract

The purpose of this retrospective study was to determine survival times and prognostic factors of dogs with visceral hemangiosarcoma (HSA) treated with surgery alone or surgery and doxorubicin. Medical records from 2 hospitals from 2005 to 2014 were searched for dogs with histopathologically confirmed visceral HSA. Data relevant to patient demographics, tumor characteristics, and outcomes were abstracted. The most common primary organ affected was the spleen; however, primary tumor location had no influence on prognosis. Twenty-three dogs were treated with surgery alone, while 14 dogs were treated with surgery and doxorubicin. There was a significant difference in survival times between dogs treated with surgery alone and with surgery followed by doxorubicin (66 days versus 274 days). Dogs with stage I tumors (196 days) had a longer median survival time (MST) than dogs with stage II (117 days) and stage III (23 days) disease. The overall MST was 179 days with a 1-year survival rate of 29.2%. (AU)

FAPESP's process: 13/16423-8 - Evaluation of the efficacy of 5-azacytidine and trichostatin-A in canine and human hemangiosarcoma cell lines
Grantee:Karen Batschinski
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)